Longeveron (LGVN) Shares Outstanding (Diluted Average) (2021 - 2026)
Longeveron (LGVN) recorded quarterly Shares Outstanding (Diluted Average) of $24.8 billion in Q1 2026, up 41.02% quarter-over-quarter from $17.6 billion in Q4 2025, and up 65.79% on a YoY basis from $15.0 billion in Q1 2025.
Longeveron (LGVN) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Longeveron's Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $24.8 billion for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 65.79% year-over-year to $24.8 billion; the TTM figure through Mar 2026 stood at $24.8 billion (up 65.79% YoY), while the FY2025 annual figure was $17.6 billion, up 86.76% from the prior year.
- Shares Outstanding (Diluted Average) was $24.8 billion for Q1 2026 at Longeveron, up from $17.6 billion in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $24.8 billion in Q1 2026 to a low of $2.1 million in Q1 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $7.4 billion across 5 years, with a median of $2.5 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) sank 89.94% in 2023, then jumped 213671.14% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $21.0 million in 2022, then jumped by 10265.24% to $2.2 billion in 2023, then surged by 333.0% to $9.4 billion in 2024, then surged by 86.76% to $17.6 billion in 2025, then jumped by 41.02% to $24.8 billion in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $24.8 billion (Q1 2026), $17.6 billion (Q4 2025), and $18.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 24.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.79 Bn |
| Dec 31, 2025 | 17.58 Bn |
| Sep 30, 2025 | 18.37 Bn |
| Jun 30, 2025 | 14.98 Bn |
| Mar 31, 2025 | 14.95 Bn |
| Dec 31, 2024 | 9.41 Bn |
| Sep 30, 2024 | 13.63 Bn |
| Jun 30, 2024 | 4.51 Bn |
| Mar 31, 2024 | 2.51 Bn |
| Dec 31, 2023 | 2.17 Bn |
| Sep 30, 2023 | 2.12 Bn |
| Jun 30, 2023 | 2.11 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 20.97 Mn |
| Sep 30, 2022 | 20.95 Mn |
| Jun 30, 2022 | 20.94 Mn |
| Mar 31, 2022 | 20.91 Mn |
| Dec 31, 2021 | 18.92 Mn |
| Sep 30, 2021 | 19.12 Mn |
| Jun 30, 2021 | 18.25 Mn |